News Quantified

KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight

Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight

Form 6-K KAZIA THERAPEUTICS LTD For: Dec 02

Form 424B3 KAZIA THERAPEUTICS LTD

Form 424B3 KAZIA THERAPEUTICS LTD

Form 424B3 KAZIA THERAPEUTICS LTD

Form 6-K KAZIA THERAPEUTICS LTD For: Nov 18

Top News Gainers

5/8 New positive data from phase IIa trial in brain cancer patients 12.8%

4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%

8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%

2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%

6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%

2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%

1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%

12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%

4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%

6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%

Top News Decliners

11/20 Kazia Therapeutics up 83% [Seeking Alpha] -18.9%

11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%

5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%

7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%

4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%

11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%

12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%

12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%

1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%

1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day